AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2016
Dec 19, 2016
33422_dirs_2016-12-19_8558b1a1-8442-4fd8-9c09-8c07e5c6ac78.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2016-12-15
Reporting Person: MAULDIN JOHN F (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-12-15 | Stock option (right to buy) | $.89 | A | 31250 | Acquired | 2026-12-15 | Common stock (31250) | Direct |
Footnotes
F1: The options vest 100% on the date of Galectin Therapeutics, Inc.'s 2017 Annual Stockholders Meeting.
More from GALECTIN THERAPEUTICS INC
Earnings Release
2026
May 15
Interim / Quarterly Report
2026
May 15
Capital/Financing Update
2026
Mar 31
Earnings Release
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Board/Management Information
2026
Mar 17
Director's Dealing
2026
Feb 9
Board/Management Information
2026
Jan 21